Sorry folks - been preoccupied elsewhereAs ATE heads into P2 in March and exits P2 by September ... I would expect that Knight sets up the shelf prospectus once again (previous one expired) somewhere between August - November. I can't remember for what amount but I think it was in the range of $200-300MM. The focus has been to reduce outstanding shares in the meantime.
Let's see if the goals remain the same or if they've changed direction since Goodman removed himself from the day-to-day. I personally think GUD would be smart to further issue the shelf prospectus and bid on additional rights for OTENA in South America and other ROW nations (Australia/NZ). This would be the perfect entry plan for additional geographies around 2026-2027. Assuming all goes to plan.
What we've learned over the past few months is ... liver issue for acute pain has been solved at ATE. Blister packs for 3-day and 7-day are being considered in addition to the 5-day regimen. Further updates for chronic pain are expected and the only question I see is ... are we talking about daily chronic pain or flare-up chronic pain? To be determined.
At that point, I see all the OTENA building blocks in place to create some very effective combination drugs using the blister pack idea. Not only can you control the daily dosing, you also taper so that you're taking the optimal each day until you're done with the regimen. No excess drug left behind to be abused.
------------------
In the meantime, it also looks like GUD is working on some secret drugs of their own. Some are expected as early as 2025.
Looks like 2026-27 could be a very interesting inflection point w.r.t. revenue for GUD - assuming all goes to plan.
As per the EXELON purchase, looks like our Parkinson's drug is likely the latest in this category. Not purchased from a drug partner ... but ... coming to market with a new partner.
Note, it isn't surprising how GUD could look to combine drug delivery in their portfolio with various versions of ATE's OTENA (future). It's a long road but the benefits could lead to GI and CV protection while adding additional reparative features. Long but extremely interesting road.
Fingers crossed as we try to understand the strategies behind the company's plays.